From COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis
The April issue of the Journal of Drugs in Dermatology features the perfect mix of medical, aesthetic, and surgical dermatology articles on topics ranging from COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
A survey was designed to capture the incidence of adverse events in G …
The April issue of the Journal of Drugs in Dermatology features the perfect mix of medical, aesthetic, and surgical dermatology articles on topics ranging from COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
A survey was designed to capture the incidence of adverse events in G … 
ABSTRACT
The risk of post-inflammatory hyperpigmentation (PIH) in patients undergoing dermatologic procedures is well known. It is especially common after laser procedures and chemical peels but can be seen with any procedure. PIH is also a sequela of acne, burns, and other trauma. High-risk patients are thought to have excessive production and abnormal distribution of melanin within the skin tha … 
Closing defects under tension in areas such as the scalp and back may be challenging during dermatologic surgery. Different techniques have been advocated to ease the placement of the first deep suture under tension, including the slip-knot stitch, pully stitch, horizontal mattress suture, pulley set-back dermal suture, and tandem pulley stitch.
INTRODUCTION
Closing defects under tension in … 
The March issue of the Journal of Drugs in Dermatology features an outstanding line-up of articles with topics ranging from OTC products for acne to Mohs Micrographic Surgery for genital skin cancer. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
Advisors agreed that OTC products and skincare recommendations, in addition to the use of prescription medications, … 
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysg …